Cytokinetics (CYTK) Tops Q4 EPS by 6c
Tweet
Share
E-mail
Get Alerts CYTK Hot Sheet
Price: $79.17 +0.50%
EPS Growth %: -46.4%
Financial Fact:
Total revenues: 59.05M
Today's EPS Names:
JFIN, KEQU, LASE, More
EPS Growth %: -46.4%
Financial Fact:
Total revenues: 59.05M
Today's EPS Names:
JFIN, KEQU, LASE, More
Join SI Premium – FREE
Cytokinetics (NASDAQ: CYTK) reported Q4 EPS of ($1.50), $0.06 better than the analyst estimate of ($1.56). Revenue for the quarter came in at $17.76 million versus the consensus estimate of $7.12 million.
For earnings history and earnings-related data on Cytokinetics (CYTK) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Apollo Global Management (APO) call put ratio 1 call to 6.8 puts a focus on a spreader of 9K contracts January 95 and 135 puts
- Morgan Stanley Upgrades QIAGEN NV (QIA:GR) (QGEN) to Overweight
- FTI Consulting names Jerome Nyssen senior managing director in Australia
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
